Dishman Carbogen Amcis valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Price multiples — at each FY-end close
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
144.44×————
0.35×————
0.80×————
10.35×————
Enterprise multiples
1.48×————
8.88×————
31.43×————
Yield
0.7%————
9.7%————
Reference — adjusted share basis
₹148.86————
₹1.03₹6.21₹0.21−₹9.79−₹1.90
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

DCAL₹148.86

Dishman Carbogen Amcis Limited

· Pharma & Health
₹ CrorePeersHIKALSOLARAPANACEABIOINDSWFTLABSAIPARENTINDOCOSMSPHARMAWINDLASMcap ₹2,334 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E————144.44
P/B————0.35
P/Sales————0.80
Price to Free Cash Flow————10.35
Enterprise Multiples
EV/Sales————1.48
EV/EBITDA————8.88
EV/EBIT————31.43
Yield
Earnings Yield %————0.69
FCF Yield %————9.66
Reference — adjusted share basis
Price (FY-end close, adj.)————148.86
EPS (adj.)-1.90-9.790.216.211.03
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.